Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIVU-107 in Advanced Solid Tumors
NCT07229313Phase 1Recruiting
- Sponsor
- Kivu Bioscience
- Start
- Nov 2025
- Primary completion
- Mar 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of KIVU-107 in solid tumor (2 arms), sponsored by Kivu Bioscience. Primary endpoints: Maximum Tolerated Dose at 18 months, Treatment Related Adverse Events at 18 months and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
KIVU-107
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07229313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229313.